Olema Pharmaceuticals is a biotechnology business based in the US. Olema Pharmaceuticals shares (OLMA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.05 – a decrease of 1.39% over the previous week. Olema Pharmaceuticals employs 80 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.05 |
|---|---|
| 52-week range | $8.51 - $17.79 |
| 50-day moving average | $12.91 |
| 200-day moving average | $12.25 |
| Wall St. target price | $27.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.05 from 2024-10-02
| 1 week (2024-09-26) | -1.39% |
|---|---|
| 1 month (2024-09-03) | 6.17% |
| 3 months (2024-07-03) | 12.93% |
| 6 months (2024-04-03) | 8.75% |
| 1 year (2023-10-03) | 7.11% |
|---|---|
| 2 years (2022-10-03) | 314.09% |
| 3 years (2021-10-01) | 29.1 |
| 5 years (2019-09-29) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -35.47% |
| Return on equity TTM | -56.4% |
| Profit margin | 0% |
| Book value | $3.97 |
| Market Capitalization | $683.8 million |
TTM: trailing 12 months
We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Olema Pharmaceuticals's shares have ranged in value from as little as $8.51 up to $17.791. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Olema Pharmaceuticals's is 2.035. This would suggest that Olema Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Olema Pharmaceuticals's beta into context you can compare it against those of similar companies.
Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Check out the best-performing ETFs so far in 2024.